Our Approach
Elite Selection
We do not index the market; we decode it. Leveraging deep scientific rigor, we isolate the specific genetic mechanisms and therapeutic assets positioned for exponential expression.
Resilient Engineering
Biotech is volatile. Our portfolio is engineered for structural resilience, utilizing advanced risk management to withstand market fluctuations while capturing the upside of clinical breakthroughs.
Global Impact
We invest in the science that changes lives. By fueling the most promising developmental therapeutic candidates, we bridge the gap between clinical development and real patient outcomes.
Leadership
David Novak
Founder & CEODavid Novak is the Founder and CEO of NOVA1 Capital, a life sciences focused investment firm established in 2023. Initially co-founded in collaboration with a leading North American healthcare specialized investment manager, Mr. Novak assumed control of the entity in 2025 and rebranded the firm as NOVA1 Capital.
Mr. Novak has over 20 years of extensive capital markets, industry, and clinical research experience which serves as the foundation for his differentiated life sciences investment strategies. Prior to founding NOVA1 Capital, he was a venture partner at Lumira Ventures, focused on developing public market investment strategies. Previously, he spent over a decade as a top-ranked biotechnology equity research analyst, culminating as a Managing Director at Raymond James.
Recognized as a “Top 40 Under 40” nominee by the Investment Industry of Canada, Mr. Novak is a leading source of biotechnology insight for CNBC, BNN/Bloomberg, and CBC.
Before making his mark as a research analyst, Mr. Novak spent a number of years working on the scientific research side of the biotechnology industry, developing molecular diagnostic tests for oncology indications. He has additionally served as a clinical research scientist investigating hereditary predisposition to cancer. His research has culminated in multiple high-impact publications within journals such as the New England Journal of Medicine. He holds a Master of Science in Human Medical Genetics from McGill University.